Extended Data Fig. 9: ARAF condensates drive RTK-related cancer drug resistance. | Nature Chemical Biology

Extended Data Fig. 9: ARAF condensates drive RTK-related cancer drug resistance.

From: Plasma membrane-associated ARAF condensates fuel RAS-related cancer drug resistance

Extended Data Fig. 9

a, MCF7 cells were treated with HRG for the indicated time points. Immunoblots are representative of three independent experiments. b, MCF7 cells treated with HRG for the indicated time points were subjected for imaging (left). Percentages of cells with PM signals were quantified, n = 3 (right). Scale bar, 5 μm. c, MCF7 cells transfected with indicated siRNAs were subjected for HRG-induced differentiation. Images were taken, bar, 50 μm (left). Oil Red staining was quantified, n = 3 (right). d, e, MDA-MB-415 cells transfected with the indicated siRNAs were subjected to cell growth, n = 4 (d) or colony formation analysis, n = 4 (e). f, MCF7 cells stably expressing the indicated constructs were subjected for HRG-induced differentiation. Images were taken, bar, 50 μm (left). Oil Red staining was quantified, n = 3 (right). g, h, 22RV1 cells transfected with the indicated siRNAs were subjected to cell growth, n = 5 (g) or colony formation analysis, n = 3 (h). i, LNCaP cells stably expressing the indicated constructs were subjected for cell growth analysis, n = 5 control and ARAF, n = 4 P/F. j, Colony formation assay in the infected LNCaP cells treated with enzalutamide, n = 4. Error bars denote the mean ± SD (biological replicates), and statistical analyses were performed using unpaired two-tailed Student’s t-test in b, c, d, e, f, g, h, i, j.

Source data

Back to article page